Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Morgan Stanley and its subsidiaries have ceased to be substantial holders in Mayne Pharma Group Limited as of June 12, 2025. This change in substantial holding, which was realized on June 16, 2025, may impact Mayne Pharma’s shareholder structure and could influence market perceptions and investor confidence.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Average Trading Volume: 962,966
Technical Sentiment Signal: Sell
Current Market Cap: A$412.7M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.